Literature DB >> 32419979

Accuracy of 68Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer.

Maija Radzina1, Mara Tirane1, Lilita Roznere1, Liene Zemniece1, Laura Dronka1, Marika Kalnina2, Edgars Mamis2, Juergen Biederer3,4, Vilnis Lietuvietis5, Arvis Freimanis5, Egils Vjaters6,3.   

Abstract

Anatomical and functional imaging plays a decisive role for detection and staging, of prostate cancer both primarily and post-treatment. While multiparametric MRI offers anatomic imaging with excellent soft tissue contrast, hybrid imaging based on positron emission tomography in combination with computed tomography (PET/CT) contributes functional imaging capacities. Since 68Ga-PSMA-11 was expected to be more efficient than the prior Choline-based PET radiotracers, it was the aim of the study to evaluate the diagnostic performance of the 68Ga-PSMA-11 PET/CT and multiparametric MRI in patients with recurrent prostate cancer and low PSA levels. 32 out of a cohort of 128 prostate cancer patients with biochemical relapse were referred for 68Ga-PSMA-11 PET/CT, MRI and bone scintigraphy. According to the histopathologically or clinically defined reference standard all results were classified as true positive, false positive, true negative or false negative. Local recurrence was present in 11/32 patients, lymph node metastases - in 13/32 patients and, bone metastases - in 6/32 patients. Against the standard of reference, sensitivity, specificity and accuracy for local recurrence of PET/CT were 63.6 %; 73.7%; 77.8%, respectively. MRI reached 90.9%; 94.7%; 92.3%, respectively. For local lymph node metastases PET/CT - 83.3%; 80.0% and 90.6%, respectively. MRI - 41.7%; 94.4%; 72.0%, respectively. For evaluation of bone metastases in PET/CT - 83.3%; 92.0%; 71.0%, respectively. Bone scintigraphy - 50.0%; 84.0%; 77.4%, respectively. In conclusion, mpMRI offered the better diagnostic accuracy in the detection of local recurrence and while PSMA PET/CT was superior in the detection of distant and lymph node metastases. AJNMMI
Copyright © 2020.

Entities:  

Keywords:  68Ga-PSMA; MRI; PSMA-PET/CT; prostate cancer; recurrence; restaging

Year:  2020        PMID: 32419979      PMCID: PMC7218697     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  23 in total

1.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Authors:  Tobias Maurer; Jürgen E Gschwend; Isabel Rauscher; Michael Souvatzoglou; Bernhard Haller; Gregor Weirich; Hans-Jürgen Wester; Matthias Heck; Hubert Kübler; Ambros J Beer; Markus Schwaiger; Matthias Eiber
Journal:  J Urol       Date:  2015-12-09       Impact factor: 7.450

Review 2.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.

Authors:  Guohua Shen; Houfu Deng; Shuang Hu; Zhiyun Jia
Journal:  Skeletal Radiol       Date:  2014-05-20       Impact factor: 2.199

Review 3.  Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.

Authors:  Thomas A Hope; Ali Afshar-Oromieh; Matthias Eiber; Louise Emmett; Wolfgang P Fendler; Courtney Lawhn-Heath; Steven P Rowe
Journal:  AJR Am J Roentgenol       Date:  2018-06-27       Impact factor: 3.959

4.  Preparation of [(68)Ga]PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based (68)Ge/(68)Ga generator.

Authors:  Raviteja Nanabala; Muhammed K Anees; Arun Sasikumar; Ajith Joy; M R A Pillai
Journal:  Nucl Med Biol       Date:  2016-05-13       Impact factor: 2.408

5.  Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.

Authors:  S Hijazi; B Meller; C Leitsmann; A Strauss; J Meller; C O Ritter; J Lotz; H-U Schildhaus; L Trojan; C O Sahlmann
Journal:  Prostate       Date:  2015-09-10       Impact factor: 4.104

Review 6.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06

Review 7.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.

Authors:  A M Hövels; R A M Heesakkers; E M Adang; G J Jager; S Strum; Y L Hoogeveen; J L Severens; J O Barentsz
Journal:  Clin Radiol       Date:  2008-02-04       Impact factor: 2.350

8.  GMP-compliant (68)Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use.

Authors:  Roeland Vis; Jules Lavalaye; Ewoudt Mw van de Garde
Journal:  EJNMMI Res       Date:  2015-04-24       Impact factor: 3.138

Review 9.  (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.

Authors:  Isabel Rauscher; Tobias Maurer; Wolfgang P Fendler; Wieland H Sommer; Markus Schwaiger; Matthias Eiber
Journal:  Cancer Imaging       Date:  2016-06-08       Impact factor: 3.909

10.  Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Authors:  Nicola Fossati; Nazareno Suardi; Giorgio Gandaglia; Carlo A Bravi; Matteo Soligo; R Jeffrey Karnes; Shahrokh Shariat; Antonino Battaglia; Wouter Everaerts; Steven Joniau; Hendrik Van Poppel; Nieroshan Rajarubendra; Inderbir S Gill; Alessandro Larcher; Alexander Mottrie; Maximilian Schmautz; Axel Heidenreich; Almut Kalz; Daniar Osmonov; Klaus-Peter Juenemann; Annika Herlemann; Christian Gratzke; Christian Stief; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2018-10-06       Impact factor: 24.267

View more
  8 in total

Review 1.  The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.

Authors:  Yishen Wang; Joao R Galante; Athar Haroon; Simon Wan; Asim Afaq; Heather Payne; Jamshed Bomanji; Sola Adeleke; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2022-07-04       Impact factor: 16.430

Review 2.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

Review 3.  PSMA PET in Imaging Prostate Cancer.

Authors:  Ioannis Tsechelidis; Alexis Vrachimis
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

Review 4.  Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography: A Practical Guide for Radiologists and Clinicians.

Authors:  Fathima Fijula Palot Manzil; Harleen Kaur; Lajos Szabados
Journal:  Cureus       Date:  2022-03-07

5.  MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.

Authors:  Cynthia Ménard; Inmaculada Navarro-Domenech; Zhihu Amy Liu; Lisa Joseph; Maroie Barkati; Alejandro Berlin; Guila Delouya; Daniel Taussky; Marie-Claude Beauchemin; Benedicte Nicolas; Samuel Kadoury; Alexandra Rink; Srinivas Raman; Aravindhan Sundaramurthy; Robert Weersink; Dominic Beliveau-Nadeau; Joelle Helou; Peter Chung
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

6.  Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer.

Authors:  P A Glemser; L T Rotkopf; C H Ziener; B Beuthien-Baumann; V Weru; A Kopp-Schneider; H P Schlemmer; A Dimitrakopoulou-Strauss; C Sachpekidis
Journal:  Cancer Imaging       Date:  2022-09-22       Impact factor: 5.605

7.  Clinical Application of the New Prostate Imaging for Recurrence Reporting (PI-RR) Score Proposed to Evaluate the Local Recurrence of Prostate Cancer after Radical Prostatectomy.

Authors:  Federica Ciccarese; Beniamino Corcioni; Lorenzo Bianchi; Antonio De Cinque; Alexandro Paccapelo; Giovanni Luca Galletta; Riccardo Schiavina; Eugenio Brunocilla; Rita Golfieri; Caterina Gaudiano
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

8.  PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?

Authors:  Winfried Brenner; Joachim Strobel; Vikas Prasad
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 10.057

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.